Latest Stock Buy or Sell? Make More Informed Decisions!
Today, Gordon Reid and The Panic-Proof Portfolio (Stockchase Research) commented about whether GGAL-Q, EG-N, LPG-N, TMUS-Q, AZN-N, JNJ-N, IMXI-Q, UBER-N, MCK-N, BKNG-Q, FCX-N, CVS-N, PLTR-Q, NVDA-Q, CB-N, RTX-N, MRK-N, ELV-N, UNH-N, GOOG-Q, INTC-Q, ADBE-Q, TOL-N, C-N, JPM-N are stocks to buy or sell.
- Page 2/2
- Next Page
If sentiment changes in China, this will move up sharply. As a cyclical, you can enter this stock at this point now. He likes FCX, which controls 8% of global copper production. Well-managed. The long-term secular story for copper is very strong--used in data centres, EVs, green energy.
Super growth rate. Uber Eats is growing. They haven't monetized the 160 million users of their app, so ads will be a big part of their business. Shares are down now because of worries of Elon Musk so tied in with the incoming president. Good tech companies adapt, and Uber can adapt. Self-driving cars will massively increase the market for ride-sharing. Trades at only 26x PE 2025, not expensive.
(Analysts’ price target is $91.08)
Premium contentIMXI provides international online payment services to customers in North and South America, the Caribbean, Africa and Asia. Recently reported earnings modestly beat expectations and analysts expect a further 5% increase in EPS. The company has been prudently using some cash reserves to reduce debt and buy back shares. It trades at 12x earnings and supports a ROE of 40%. We recommend setting a stop-loss at $18, looking to achieve $26 -- upside potential of 19%. Yield 0%
(Analysts’ price target is $26.40)Premium contentThe consumer product monster has increased debt lately, but analysts feel comfortable with the low debt to earnings ratio. This is allowing the company to continue growing cash reserves. It trades at 24x earnings and supports a 20% ROE. We recommend setting a stop-loss at $133 looking to achieve $174 -- upside potential of 19%. Yield 3.3%
(Analysts’ price target is $174.28)Premium contentThe big pharma is developing a GLP-1 weight loss treatment that avoids injections -- a big game changer - and trials are looking good. The stock trades at 32x earnings and supports a 16% ROE. We recommend setting a stop-loss at $52, looking to achieve $88 -- upside potential of 30%. Yield 2.2%
(Analysts’ price target is $88.01)Premium contentOur PAST TOP PICK with TMUS has triggered its stop at $225. To remain disciplined, we recommend covering the position at this time. Combined with our previous guidance, this will result in a net investment gain of 41%
Premium contentPremium contentPremium content
He sold it 3 months ago after holding it a long time. Shares keep falling. They fired their CEO. On paper, this stock looked good--reasonable valuation and good growth prospects, but they could never execute. There was always one piece in the vertical integration that failed them. That's why he left. The shares look cheap now, but can get cheaper. This is a value trap.